---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105807"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:49:51.553951+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026

## Summary
- Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
- Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.
- No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.
- If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.
- Company will monitor MVLS and consider available options to address the deficiency.

## SEC filing metadata
- accession: 0000950170-25-105807
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/0000950170-25-105807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/fblg-20250725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105807
- JSON: https://secwatch.observer/filing/0000950170-25-105807.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105807.txt

## Key facts
- Listing & Compliance Notices
  FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: August 4, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35.0 million that is required for continued listing on The Nasdaq Capital Market (the “Notice”). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market subject
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/0000950170-25-105807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.